Early Cytokine Removal in Critical COVID-19 Patients with Extracorporeal Therapies (HA-380 plus High Volume Hemofiltration) May Prevent Progression of Acute Respiratory Distress Syndrome: Case Report
Author(s) -
Gonzalo RamírezGuerrero,
Vicente Torres Cifuentes,
Romyna Baghetti Hernández,
Francisco Villagrán Cortés,
Simón Rojas Doll,
Rocio Oliva Alarcón,
Cristian Lucero Córdova,
Pablo Flores Fernandez,
Osvaldo Garay Coloma
Publication year - 2020
Publication title -
blood purification
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.686
H-Index - 57
eISSN - 1421-9735
pISSN - 0253-5068
DOI - 10.1159/000512982
Subject(s) - medicine , hemofiltration , extracorporeal , pneumonia , covid-19 , acute respiratory distress , cytokine release syndrome , respiratory distress , intensive care medicine , extracorporeal membrane oxygenation , anesthesia , lung , disease , hemodialysis , infectious disease (medical specialty)
We present the case of a patient who suffered from acute respiratory distress syndrome caused by pneumonia associated with COVID-19 and cytokine release syndrome. This patient received a high-volume hemofiltration plus adsorption, solving the hemodynamic deterioration, pulmonary infiltrates, and gas exchange. Our clinical case proposes that the extracorporeal therapies can have a role in the management of severe COVID-19.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom